Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies

Overview

Journal Clin Med Insights Circ Respir Pulm Med

Publisher Sage Publications

Date 2016 Apr 16

PMID 27081322

Citations 8

Authors

Hajime Yoshifuji

Affiliations

Soon will be listed here.

Abstract

Various autoantibodies are seen in idiopathic inflammatory myopathies. Among myositis-specific antibodies, anti-aminoacyl-tRNA synthetase and anti-melanoma differentiation-associated protein 5 (MDA5) antibodies are associated with interstitial lung disease (ILD). Anti-MDA5 antibodies are associated with dermatomyositis (DM) or clinically amyopathic DM complicated with rapidly progressive ILD. In anti-MDA5-positive patients, a random ground-glass attenuation pattern is a characteristic finding of ILD in chest high-resolution computed tomography. Conversely, anti-aminoacyl-tRNA synthetase antibodies are not associated with rapidly progressive ILD but with chronic ILD. DM or clinically amyopathic DM patients with anti-MDA5, and characteristic high-resolution computed tomography findings are highly likely to have devastating ILD and need aggressive treatment.

Citing Articles

Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study.

Xin H, He P, Xi B, Wang Z, Wang H, Wang F BMC Pulm Med. 2025; 25(1):40.

PMID: 39863893 PMC: 11762128. DOI: 10.1186/s12890-025-03512-4.

Clinical features and prognosis of anti-MDA5-positive dermatomyositis with coexistent anti-aminoacyl-tRNA synthetase antibodies.

Wang G, Yan D, Weng C, Xue L, Liu Z Clin Rheumatol. 2025; 44(2):767-774.

PMID: 39751977 DOI: 10.1007/s10067-024-07298-4.

The molecular mechanism underlying dermatomyositis related interstitial lung disease: evidence from bioinformatic analysis and validation.

Zeng L, Tang Y, Zhang Y, Yue L, Ma G, Ye X Front Immunol. 2023; 14:1288098.

PMID: 37928522 PMC: 10622801. DOI: 10.3389/fimmu.2023.1288098.

Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.

Li M, Zhao X, Liu B, Zhao Y, Li X, Ma Z Front Immunol. 2023; 14:1209282.

PMID: 37691917 PMC: 10483132. DOI: 10.3389/fimmu.2023.1209282.

Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis.

Liu T, Li W, Zhang Z, Jiang T, Fei Y, Huang J BMC Pulm Med. 2022; 22(1):316.

PMID: 35978395 PMC: 9382756. DOI: 10.1186/s12890-022-02106-8.

References

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K . Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(9):1713-9. DOI: 10.1093/rheumatology/keq149. View

Bluthner M, Mahler M, Muller D, Dunzl H, BAUTZ F . Identification of an alpha-helical epitope region on the PM/Scl-100 autoantigen with structural homology to a region on the heterochromatin p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol Med (Berl). 2000; 78(1):47-54. DOI: 10.1007/s001099900072. View

Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M . Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2011; 64(2):513-22. DOI: 10.1002/art.33403. View

Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S . Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011; 105(8):1238-47. DOI: 10.1016/j.rmed.2011.03.022. View

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

Targoff I, Johnson A, Miller F . Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990; 33(9):1361-70. DOI: 10.1002/art.1780330908. View

Lega J, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M . The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014; 13(9):883-91. DOI: 10.1016/j.autrev.2014.03.004. View

Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D . Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006; 39(3):233-41. DOI: 10.1080/08916930600622884. View

Dalakas M . Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991; 325(21):1487-98. DOI: 10.1056/NEJM199111213252107. View

10.

Targoff I . Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol. 1990; 144(5):1737-43. View

11.

Herbert M, Stammen-Vogelzangs J, Verbeek M, Rietveld A, Lundberg I, Chinoy H . Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2015; 75(4):696-701. PMC: 4699257. DOI: 10.1136/annrheumdis-2014-206691. View

12.

Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X . Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012; 64(10):1602-10. DOI: 10.1002/acr.21728. View

13.

Fathi M, Helmers S, Lundberg I . KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2011; 271(6):589-97. DOI: 10.1111/j.1365-2796.2011.02459.x. View

14.

Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K . HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011; 105(9):1380-7. DOI: 10.1016/j.rmed.2011.05.006. View

15.

Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K . Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2006; 46(1):25-8. DOI: 10.1093/rheumatology/kel161. View

16.

Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert E, Genth E . Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 1996; 39(5):868-76. DOI: 10.1002/art.1780390521. View

17.

Mimori T, Imura Y, Nakashima R, Yoshifuji H . Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19(6):523-9. DOI: 10.1097/BOR.0b013e3282f01a8c. View

18.

Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel J . Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore). 2012; 91(2):95-102. DOI: 10.1097/MD.0b013e31824d9cec. View

19.

Aggarwal R, Cassidy E, Fertig N, Koontz D, Lucas M, Ascherman D . Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2013; 73(1):227-32. PMC: 4031026. DOI: 10.1136/annrheumdis-2012-201800. View

20.

Bunn C, Bernstein R, Mathews M . Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med. 1986; 163(5):1281-91. PMC: 2188100. DOI: 10.1084/jem.163.5.1281. View